-5%
Biganib is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
Non-small cell lung cancer (NSCLC) is a type of lung cancer that occurs when abnormal cells form and multiply in lung tissues. It is one of the two main types of lung cancer, with the other being small-cell lung cancer. NSCLC is further categorized into three main types:
- Adenocarcinoma: This type forms in cells that secrete mucus and other substances. It usually develops in the outer portions of the lung. Adenocarcinoma can affect both smokers and non-smokers and is more likely to occur at a younger age.
- Squamous cell carcinoma: Originating in squamous cells that line the inside of airways, this type typically forms in the central part of the lungs. It is associated with a history of smoking.
- Large cell carcinoma: Also known as undifferentiated carcinoma, this type can form in any part of the lung. It tends to grow and spread quickly, making it more challenging to treat.
Other less common subtypes of NSCLC include sarcomatoid carcinoma and adenosquamous carcinoma.
Prevalence: NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases.
Symptoms: Common symptoms of NSCLC include:
- Shortness of breath
- Persistent cough
- Chest pain or discomfort
- Wheezing
- Coughing up blood
- Hoarseness
- Loss of appetite
- Unexplained weight loss
- Fatigue
- Difficulty swallowing
Some cases may be asymptomatic and discovered during routine screenings.
Risk Factors:
- Smoking (most significant risk factor)
- Asbestos Exposure
- Metal and mineral dust exposure
- Radon exposure
- Chronic obstructive pulmonary disease (COPD)
- Air pollution
- Pulmonary fibrosis
- HIV/AIDS
- Previous radiation therapy to the chest
Diagnosis: Diagnosis involves a series of tests, including physical examination, laboratory tests, imaging (X-rays, CT scans), biopsy, and other procedures like bronchoscopy or thoracentesis.
Staging: Staging determines the extent of cancer spread and includes stages 0 to IV:
- Stage 0: Abnormal cells in the top layers of lung tissue.
- Stage I: Small tumor fully contained in the lung.
- Stage II: Larger tumor, may involve nearby lymph nodes.
- Stage III: Larger tumor with possible spread to surrounding tissues and lymph nodes.
- Stage IV: Metastatic cancer that has spread to other parts of the body.
Treatment: Treatment options depend on the stage and type of NSCLC and may include:
- Surgery (lobectomy, lung resection)
- Radiofrequency ablation (RFA)
- Radiation therapy
- Chemotherapy
- Targeted drug therapy
- Immunotherapy
Recovery time varies, and the prognosis is influenced by factors such as stage, type, and overall health.
Prevention: While NSCLC cannot always be prevented, reducing risk factors like smoking can significantly lower the risk. Early detection through screenings is crucial for better outcomes.
The prognosis for NSCLC varies based on factors like stage, type, and overall health. Early detection and treatment improve the chances of a cure, and even in cases where a cure is not possible, managing symptoms can lead to a fulfilling life. Survival rates are estimates, and individual responses to treatment may differ. Consultation with a healthcare provider provides more personalized information.